Genotype,Phenotype,and Virtual Phenotype: Who Needs What and Why?

Abstract

References

Hirsch MS , Brun-Vezinet F , Clotet B , et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128.

Baxter JD , Mayers DL , Wentworth DN , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-F93.

Durant J , Clevenbergh P , Halfon P , et al. Drug-resistance genotyping in HIV-1 therapy: The VIRAPAPT randomised controlled trial. Lancet 1999;353:2195-2199.

Tural C , Ruiz L , Holtzer C , et al. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002;16:209-218.

Durant J , Clevenbergh P , Garraffo R , et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the VIRADAPT Study. AIDS 2000;14:1333-1339.

Cohen CJ , Hunt S , Sension M , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579-588.

Melnick D , Rosenthal J , Cameron M , et al. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. 7th Conference on Retroviruses and Opportunistic Infections. January 30-February 4, 2000. San Francisco, CA. (Abstract 786).

Haubrich R , Keiser P , Kemper C , and the CCTG Study Team . CCTG 575: A randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 2001;6(Suppl 1):63.

Meynard JL , Vray M , Morand-Joubert L , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.

10.

Wegner SA , Wallace M , Tasker S , et al. Long-term clinical efficacy of resistance testing: Results of the CERT trial. Antivir Ther 2002; 7:S129.

11.

Katzenstein DA , Bosch RJ , Hellmann N et al. Phenotypic susceptibility and virologic outcome in nucleoside-experienced patients receiving three or four antiretrovirals. AIDS 2003;17:821-830.

12.

Shulman NS , Hughes MD , Winters MA , et al. Subtle decreases in stavudine phenotypic susceptibility predicts poor virologic response to stavudine monotherapy in zidovudine-experienced patients. J Acquir Immune Defic Syndr 2002;31:121-127.

13.

Lanier ER , Hellmann N , Scott J , et al. Determination of a clinically relevant phenotypic resistance “cutoff” for abacavir using the PhenoSense assay. 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, IL. (Abstract 254).

14.

Zolopa AR , Shafer RW , Warford A , et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999;131:813-821.

15.

Ross L , Liao Q , Gao H , et al. Impact of HIV type 1drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. AIDS Res Hum Retroviruses 2001;17:1379-1385.

16.

Patick AK , Duran M , Cao Y , et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents and Chemotherapy 1998;42:2637-2644.

17.

Condra JH , Schleif WA , Blahy OM , et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.

18.

Kemper CA , Witt MD , Keiser PH , et al. Sequencing of protease inhibitor therapy: Insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001;15:609-615.

19.

Boden D , Hurley A , Zhang L , et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.

20.

Briones C , Perez-Olmeda M , Rodriguez C , et al. Primary genotypic and phenotypic HIV-1 drug resistance recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001;26:145-150.

21.

Duwe S , Brunn M , Altmann D , et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German seroconverter study. J Acquir Immune Defic Syndr 2001;26:266-273.

22.

Grant RM , Hecht FM , Warmerdam M , et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.

23.

Little SJ , Holte S , Routy JP , et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.

24.

Weinstein MC , Goldie SJ , Losina E , et al. Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.

25.

D’Aquila RT , Schapiro JM , Brun-Vezinet F , et al. Drug resistance mutations in HIV-1. Top HIV Med 2002;10:21-25.

26.

Sturmer M , Doerr HW , Staszewski S , et al. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 2003:8:239-244.

27.

Hertogs K , Bloor S , Demp SD , et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS 2000;14:1203-1210.

28.

Betts BJ , Shafer RW . Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation. J Clin Microbiol 2003;41:2792-2794.

29.

Shafer RW . Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-277.

30.

The EuroGuidelines Group for HIV Resistance . Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. AIDS 2001;15:309-320.

31.

Mazzotta F , Lo Caputo S , Torti C , et al. Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003;32:268-280.

32.

Torti C , Quiros-Roldan E , Scudeller L , et al. GenPheRex Group of the Ma.S.Te.R. Cohort. Characterization of virological immunological responses in a closely followed cohort of heavily pretreated patients: Evidence from the GenPheRex Study. HIV Med 2003;4:263-270.

33.

Miller V , Cozzi-Lepri A , Hertogs K , et al. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 2000;5:49-55.

34.

Jiang H , Deeks SG , Kuritzkes DR , et al. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis 2003;188:1001-1008.

35.

Deeks SG , Wrin T , Liegler T , et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patents with detectable viremia. N Engl J Med 2001;344:472-480.

36.

DeGruttola V , Dix L , D’Aquila R , et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiv Ther 2000;5:41-48.

37.

Margot NA , Isaacson E , McGowan I , Cheng A , et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002;16:1227-1235.

38.

Wang D , Larder B . Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 2003;188:653-660.

39.

Kempf DJ , Isaacson JD , King MS , et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002;7:165-174.

40.

Parkin NT , Chappey C , Petropoulos CJ . Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patters and amprenavir cross-resistance. AIDS 2003;17:955-961.

41.

Paolucci S , Baldanti F , Zavattoni M , et al. Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. J Antimicrob Chemother 2003;51:135-139.

42.

Lanier R , Danehower S , Daluge S , et al. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. June 24-27, 1998. Lake Maggiore, Italy. (Abstract 52).

43.

Brun-Vezinet F , Descamps D , Ruffault A , et al. Narval (ANRS 088) Study group. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003;17:1795-1802.

44.

Shulman N , Bosch R , Wang N , et al. Impact of M184V/I mutation on HIV phenotypic resistance to nucleoside analogs (nRTIs) in nRTI-experienced patients. 41st ICAAC. December 16-29, 2001. Chicago, USA. (Abstract I-1759).

45.

Ravela J , Betts BJ , Brun-Vezinet F , et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003;33:8-14.

46.

Bosch RJ , Downey GF , Katzenstein DA , et al. For the ACTG 364 Study Team. Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS 2003;17:2395-2396.